Shenzhen Kangtai Biological Products
22°32′48″N 113°56′37″E / 22.5467°N 113.9437°E
| Company type | Public | ||||||
|---|---|---|---|---|---|---|---|
| SZSE: 300601 | |||||||
| ISIN | CNE100002Q33  | ||||||
| Founded | September 8, 1992 | ||||||
| Founder | Du Weimin | ||||||
| Headquarters | 6 Kefa Road, Science and Technology Park, Nanshan District, Shenzhen, , China | ||||||
Number of employees | 2043 | ||||||
| Chinese name | |||||||
| Simplified Chinese | 深圳康泰生物制品股份有限公司 | ||||||
| |||||||
| Website | en | ||||||
Shenzhen Kangtai Biological Products (Chinese: 深圳康泰生物制品股份有限公司, SZSE: 300601), also known as BioKangtai (Chinese: 康泰生物), is a Chinese biopharmaceutical company that develops, manufactures and markets vaccines and other vaccine products.
Kangtai develops the Minhai COVID-19 vaccine and has the exclusive right to manufacture the Oxford–AstraZeneca COVID-19 vaccine in mainland China.
References
- ^ "Scandal Dogs AstraZeneca's Vaccine Partner in China". The New York Times. 7 January 2021. Retrieved 1 August 2021.
- ^ "Shenzhen Kangtai Biological Products Co Ltd". Bloomberg. Retrieved 1 August 2021.
- ^ "Kangtai Biological's COVID-19 vaccine gets emergency use approval in China". Reuters. 14 May 2021. Retrieved 1 August 2021.
- ^ "AstraZeneca's China partner expects to be able to make 400 million COVID-19 vaccine doses a year". Reuters. 2 February 2021. Retrieved 1 August 2021.
 | This Chinese corporation or company article is a stub. You can help Wikipedia by expanding it. |